Finally, the ability of SLC2A1 and NDUFB9 to distinguish between OA and RA was evaluated, and the results suggested that NDUFB9 holds promise as a potential biomarker for distinguishing OA from RA. Here, NDUFB9 is linked to rheumatoid arthritis.